Vericel to Report First-Quarter 2022 Financial Results on May 4, 2022
April 20 2022 - 8:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced the following webcast and conference call to discuss its
first-quarter 2022 financial results and business highlights.
What: |
Vericel Corporation First-Quarter 2022 Earnings Call |
|
|
When: |
Wednesday, May 4, 2022 at 8:30am (ET) |
|
|
Where: |
http://investors.vcel.com/events-presentations |
|
|
How: |
The conference call will be available live on the Investor
Relations section of the Vericel website at
http://investors.vcel.com/events-presentations. Please access the
site at least 15 minutes prior to the scheduled start time in order
to download the required audio software if necessary. Presentation
slides for the conference call will be available on the webcast and
on the Investor Relations section of the Vericel website. |
To participate by telephone, please call (877) 312-5881 and
reference Vericel Corporation’s first-quarter 2022 earnings call.
If calling from outside the U.S., please use the international
phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events-presentations
until May 4, 2023. The conference ID is 7195435.
About Vericel Corporation
Vericel is a leader in advanced therapies for the sports
medicine and severe burn care markets. The company markets two cell
therapy products in the United States. MACI® (autologous cultured
chondrocytes on porcine collagen membrane) is an autologous
cellularized scaffold product indicated for the repair of
symptomatic, single or multiple full-thickness cartilage defects of
the knee with or without bone involvement in adults. Epicel®
(cultured epidermal autografts) is a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. The
company also holds an exclusive license for North American
commercial rights to NexoBrid®, a registration-stage biological
orphan product for debridement of severe thermal burns. For more
information, please visit www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2022 Vericel
Corporation. All rights reserved.
Investor Contacts:Eric Burnsir@vcel.com +1
(734) 418-4411
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024